Switzerland makes 400 million francs available for coronavirus vaccine
The Swiss government has increased its vaccine fund by CHF100 million, bringing the total funds available for the vaccine to CHF400 million.
The decision was made on Wednesday afternoon. Swiss Health Minister Alain Berset made the announcement, saying the vaccine would be made available to the entire Swiss population.
The money allocated goes towards the purchase of the vaccine doses and does not include the costs associated with the vaccination process.
Swiss media site 20 Minutes reports that the vaccine is estimated to cost 40 francs per person. Each person requires two doses, with each needle costing 20 francs.
According to Stefan Kuster, Head of the Communicable Diseases Section at the Federal Office of Public Health, was unable to put a concrete timeline on when the vaccine would be available, but did tell a media conference on Tuesday that people in risk groups and those around them would be first in line to be vaccinated.
EXPLAINED: When will Switzerland roll out a Covid-19 vaccine?
Health workers are also expected to have early access to the vaccine.
Comments
See Also
The decision was made on Wednesday afternoon. Swiss Health Minister Alain Berset made the announcement, saying the vaccine would be made available to the entire Swiss population.
The money allocated goes towards the purchase of the vaccine doses and does not include the costs associated with the vaccination process.
Swiss media site 20 Minutes reports that the vaccine is estimated to cost 40 francs per person. Each person requires two doses, with each needle costing 20 francs.
According to Stefan Kuster, Head of the Communicable Diseases Section at the Federal Office of Public Health, was unable to put a concrete timeline on when the vaccine would be available, but did tell a media conference on Tuesday that people in risk groups and those around them would be first in line to be vaccinated.
EXPLAINED: When will Switzerland roll out a Covid-19 vaccine?
Health workers are also expected to have early access to the vaccine.
Join the conversation in our comments section below. Share your own views and experience and if you have a question or suggestion for our journalists then email us at [email protected].
Please keep comments civil, constructive and on topic – and make sure to read our terms of use before getting involved.
Please log in here to leave a comment.